Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
J Orthop Trauma. 2020 Jan;34(1):30-41. doi: 10.1097/BOT.0000000000001626.
Fracture-related infection (FRI) is a major complication in musculoskeletal trauma and one of the leading causes of morbidity. Standardization of general treatment strategies for FRI has been poor. One of the reasons is the heterogeneity in this patient population, including various anatomical locations, multiple fracture patterns, different degrees of soft-tissue injury, and different patient conditions. This variability makes treatment complex and hard to standardize. As these infections are biofilm-related, surgery remains the cornerstone of treatment, and this entails multiple key aspects (eg, fracture fixation, tissue sampling, debridement, and soft-tissue management). Another important aspect, which is sometimes less familiar to the orthopaedic trauma surgeon, is systemic antimicrobial therapy. The aim of this article is to summarize the available evidence and provide recommendations for systemic antimicrobial therapy with respect to FRI, based on the most recent literature combined with expert opinion. LEVEL OF EVIDENCE:: Therapeutic Level V. See Instructions for Authors for a complete description of levels of evidence.
骨折相关感染(FRI)是肌肉骨骼创伤的主要并发症之一,也是发病率的主要原因之一。FRI 的一般治疗策略的标准化一直很差。其中一个原因是患者人群的异质性,包括不同的解剖部位、多种骨折模式、不同程度的软组织损伤和不同的患者状况。这种可变性使得治疗变得复杂且难以标准化。由于这些感染与生物膜有关,手术仍然是治疗的基石,这需要多个关键方面(例如,骨折固定、组织取样、清创和软组织管理)。另一个重要方面,有时对骨科创伤外科医生来说不太熟悉,是全身抗菌治疗。本文的目的是总结现有证据,并根据最新文献结合专家意见,就 FRI 的全身抗菌治疗提供建议。证据水平:治疗水平 V。有关证据水平的完整描述,请参见作者说明。